Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioAtla, Inc. - Common Stock (NQ:BCAB)

0.6948 -0.0032 (-0.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 456,184
Open 0.6929
Bid (Size) 0.6810 (10)
Ask (Size) 0.7068 (6)
Prev. Close 0.6980
Today's Range 0.6701 - 0.7357
52wk Range 0.2400 - 2.525
Shares Outstanding 47,637,321
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
These stocks are moving in today's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill

Performance

YTD
+13.2%
+13.2%
1 Month
+1.0%
+1.0%
3 Month
+93.5%
+93.5%
6 Month
+39.8%
+39.8%
1 Year
-65.6%
-65.6%

More News

Read More
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Earnings Scheduled For August 7, 2025
Via Benzinga
Earnings Scheduled For May 6, 2025
Via Benzinga
A Preview Of BioAtla's Earnings
Via Benzinga
Earnings Outlook For BioAtla
Via Benzinga
BioAtla (BCAB) Q2 Loss Narrows 27%
Via The Motley Fool
Topics Intellectual Property
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
BCAB Stock Earnings: BioAtla Meets EPS for Q2 2024
Via InvestorPlace
BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024
Via InvestorPlace
BCAB Stock Earnings: BioAtla Beats EPS for Q4 2023
Via InvestorPlace
Earnings Scheduled For March 27, 2025
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
BioAtla: Q4 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
From Context Therapeutics Inc.
Via GlobeNewswire
'Big Short' Fame Michael Burry Bets Big On China, Reveals Alibaba As Top Holding — JD.com And Baidu Also Feature On Scion's Portfolio
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga

Frequently Asked Questions

Is BioAtla, Inc. - Common Stock publicly traded?
Yes, BioAtla, Inc. - Common Stock is publicly traded.
What exchange does BioAtla, Inc. - Common Stock trade on?
BioAtla, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioAtla, Inc. - Common Stock?
The ticker symbol for BioAtla, Inc. - Common Stock is BCAB on the Nasdaq Stock Market
What is the current price of BioAtla, Inc. - Common Stock?
The current price of BioAtla, Inc. - Common Stock is 0.6948
When was BioAtla, Inc. - Common Stock last traded?
The last trade of BioAtla, Inc. - Common Stock was at 10/30/25 04:00 PM ET
What is the market capitalization of BioAtla, Inc. - Common Stock?
The market capitalization of BioAtla, Inc. - Common Stock is 33.10M
How many shares of BioAtla, Inc. - Common Stock are outstanding?
BioAtla, Inc. - Common Stock has 33M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.